SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001178913-21-002696
Filing Date
2021-08-13
Accepted
2021-08-13 08:06:57
Documents
34
Period of Report
2021-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q cmmb10q0621.htm   iXBRL 10-Q 698481
2 CERTIFICATION OF CHIEF EXECUTIVE OFFICER exhibit_31-1.htm EX-31.1 15737
3 CERTIFICATION OF CHIEF FINANCIAL OFFICER exhibit_31-2.htm EX-31.2 15160
4 CERTIFICATION OF CHIEF EXECUTIVE OFFICER exhibit_32-1.htm EX-32.1 6717
5 CERTIFICATION OF CHIEF FINANCIAL OFFICER exhibit_32-2.htm EX-32.2 6431
  Complete submission text file 0001178913-21-002696.txt   2170110

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE cmmb-20210630.xsd EX-101.SCH 20920
7 XBRL CALCULATION FILE cmmb-20210630_cal.xml EX-101.CAL 24379
8 XBRL DEFINITION FILE cmmb-20210630_def.xml EX-101.DEF 68825
9 XBRL LABEL FILE cmmb-20210630_lab.xml EX-101.LAB 141266
10 XBRL PRESENTATION FILE cmmb-20210630_pre.xml EX-101.PRE 114209
11 EXTRACTED XBRL INSTANCE DOCUMENT cmmb10q0621_htm.xml XML 154971
Mailing Address KIRYAT ATIDIM, BUILDING 7 TEL AVIV L3 6158002
Business Address KIRYAT ATIDIM, BUILDING 7 TEL AVIV L3 6158002 972-77-331-0156
Chemomab Therapeutics Ltd. (Filer) CIK: 0001534248 (see all company filings)

IRS No.: 813676773 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38807 | Film No.: 211169799
SIC: 2834 Pharmaceutical Preparations